Pharnext’s PLEODRUG™, PXT3003, to be Featured in Multiple Presentations at the 2017 Peripheral Nerve Society Meeting
27.6.2017 15:45 | Business Wire
Pharnext SA (FR00111911287 - ALPHA) (Paris:ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced that the Company will present an update from its ongoing pivotal Phase 3 clinical trial evaluating lead PLEODRUG™ PXT3003, in development for the treatment of Charcot-Marie-Tooth type 1A disease (CMT1A), in a poster and at an oral session at the upcoming 2017 Peripheral Nerve Society Meeting. Additional data related to PXT3003 and CMT1A will also be featured in two posters at the meeting, which is being held on July 8-12 in Sitges, Spain.
Clinical Trials Update sessions - Tuesday July 11, 2017, 7:30am to
- Oral Presentation “Status of the ongoing multi-center, randomised, double-blind, placebo controlled, pivotal phase III study to assess the efficacy and safety of PXT3003 for CMT1A (PLEO-CMT).” R. Goedkoop et al.
- Presenter: René Goedkoop, MD, Chief Medical Officer, Pharnext, Issy-les-Moulineaux, France
Poster Viewing Session #2 – Monday July 10, 2017
- Poster P2_81 (abstract 34948) “Sensitivity to change of the Charcot-Marie-Tooth Neuropathy Score (CMTNS) and Overall Neuropathy Limitation Scale (ONLS) in a database of French patients with CMT1A.” J. Foucquier et al.
Poster Viewing Session #4 – Wednesday July 12, 2017
- Poster P4_42 (abstract 34857) “PXT3003, a fixed combination of baclofen, naltrexone and sorbitol, for the treatment of Charcot-Marie-Tooth disease type 1A (CMT1A): status of a multicenter, double-blind, placebo-controlled, pivotal Phase III study (PLEOMCT).” S. Attarian et al.
- Poster P4_58 (abstract 34930) “The combinational drug PXT3003 improves neuromuscular function in an animal model of Charcot-Marie-Tooth type 1A disease.” T. Prukop et al.
All abstracts will be published in the Journal of the Peripheral Nervous System (JPNS) accessible at: www.wileyonlinelibrary.com/journal/JPNS
Pharnext is an advanced clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The Company identifies and develops synergic combinations of repositioned drugs at new optimal lower doses. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team.
The company Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN code: FR00111911287).
For more information, visit www.pharnext.com
Xavier Paoli, +33 (0)1 41 09 22 30
Chief Commercial Officer
Pierre Schwich, +33 (0)1 41 09 22 30
Chief Financial Officer
Investor Relations (Europe)
MC Services AG
Anne Hennecke, +49 211 529252 22
Investor Relations (U.S.)
Stern Investor Relations, Inc.
Sarah McCabe, +1 212-362-1200
Financial Communication (France)
Emmanuel Huyn, +33 (0)1 44 71 20 40
Media Relations (Europe)
+33 (0)1 44 54 36 64
Media Relations (U.S.)
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Xilam: H1 2017 Revenue: +67%20.7.2017 16:00 | Pressemelding
Regulatory News: The Xilam Group (Paris:XIL) posted consolidated H1 2017 revenue of EUR 9.239 million, an increase of 67%. The revenue breakdown is as follows: In EUR 000 30.06.2017 (1) 30.06.2016 Change New productions(2) 4,571 4,036 +13.3% Catalogue 4,652
Natalia Vodianova Joins PicsArt as Head of Aspiration20.7.2017 13:00 | Pressemelding
PicsArt, the leading image editing app and creative social network, today announced the appointment of Natalia Vodianova, the supermodel and philanthropist, as Head of Aspiration. In this new role, Natalia will inspire and suggest opportunities to drive positive change through creativity. She has also joined the company’s advisory board. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170720005372/en/ Natalia Vodianova, the supermodel and philanthropist, joins PicsArt as Head of Aspiration. (Photo: Business Wire) “We are thrilled to welcome a talent and role model like Natalia into our family,” said PicsArt CEO Hovhannes Avoyan. “Natalia has been deeply involved in bringing creative inspiration to the world through fashion and social commitment. She’ll help connect the fashion world and the
CloudHealth Technologies Expands Business in Europe20.7.2017 13:00 | Pressemelding
CloudHealth Technologies, the leader in cloud service management, today announced that it is expanding its customer base, partner list and business operations in the European region. Helping to fuel the expansion is $46 million in Series D funding, which the company secured in June. The funding round will help CloudHealth Technologies scale international operations and double the size of its global workforce. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170720005189/en/ CloudHealth Technologies Expands Business in Europe (Photo: Business Wire) Cloud adoption in EMEA is growing steadily, with the market projected to reach €44.8 billion by the year 2020, according to Market Research & Statistics1. As enterprises turn to the cloud to build apps and manage operations, they improve
Pacific Drilling Announces Early Consent Deadline Results20.7.2017 13:00 | Pressemelding
Pacific Drilling V Limited (the “Issuer”), a wholly owned subsidiary of Pacific Drilling S.A. (NYSE: PACD) (together with its subsidiaries, the “Company”) announced today the results, as of 5:00 p.m. Eastern Daylight Time on July 19 (the “Early Consent Deadline”) of its previously announced private consent solicitation in respect of its 7.25% Senior Secured Notes due December 1, 2017 (the “Notes”) pursuant to which the Issuer is soliciting the consent of the holders of Notes to an extension of the maturity date of the Notes to June 1, 2018 in order to give the Company more time to negotiate a refinancing transaction or undertake a holistic restructuring with all of its creditors (the “Solicitation”). At the Early Consent Deadline, the Issuer has received consents of holders of the Notes comprising less than 66 2/3% of the aggregate principal amount of the Notes (disregarding Notes held by the
Watch BizWireTV: AR/VR Innovator Leap Motion Looks to Expand Globally and Stephen Curry, Serena Williams and Other Sports Stars Win Big at Nickelodeon’s Kids’ Choice Sports 201720.7.2017 12:08 | Pressemelding
On the latest BizWireTV, catch the latest Quick Biz Hits and who’s using some Star Power. Also see what’s happening in the startup world with the Accelerator Report, featuring the VC Watch and this week’s Startup Standout. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170720005302/en/ BizWireTV is hosted by Jordyn Rolling (Photo: Business Wire) Now you can watch BizWireTV, and the latest breakthroughs in tech from the biggest brands, on any screen you want by downloading the new app through the Apple TV and iPhone App Store and Google Play for Android devices. Sponsored Headline The State of Channel Marketing: IDG Research study reveals crossroads, opportunity for channel marketers. Top of the Wire
21st Century Fox’s Response to Statement by the UK’s Secretary of State for Digital, Culture, Media and Sport20.7.2017 12:05 | Pressemelding
21st Century Fox (21CF) notes today’s statement by the Secretary of State for Digital, Culture, Media and Sport that she continues to consider the representations that have been made before she makes her decision on 21CF’s proposed acquisition of the remaining shares of Sky. We welcomed the recent statement by the Secretary of State that “Ofcom is unequivocal” regarding 21CF’s genuine commitment to broadcasting standards, following advice from the independent regulator which found “there are no broadcasting standards concerns which may justify a reference by the Secretary of State to the Competition and Markets Authority.” For over 25 years, 21CF and Sky have been proud broadcasters of good standing in the UK, a responsibility we take very seriously. We also welcomed Ofcom’s decision of 29th June that Sky would remain ‘fit and proper’ to hold a broadcasting licence after this proposed
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom